Amarin Says It Will Complete Cardiovascular Outcomes Trial For Its Fish Oil Pill

September 16, 2014 5:00 AM

7 0

After nearly a year of uncertainty, Amarin announced its commitment to complete REDUCE-IT (Reduction of Cardiovascular Events with EPA – Intervention Trial). The trial is designed to test the effects on cardiovascular outcomes of Vascepa, the company’s high EPA omega-3 prescription fish oil product, in people with moderately elevated triglyceride levels between 200-499 mg/dL.

Last year the company said it might discontinue support of the trial, which began in 2011, after the FDA turned down the company’s application for an expanded indication for Vascepa. Currently Vascepa is only approved for use in the small population of people with triglyceride levels of 500 mg/dL or...

Read more

To category page